BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37244804)

  • 1. Advances in remission induction therapy for ANCA-associated vasculitis.
    Morris A; Geetha D
    Best Pract Res Clin Rheumatol; 2023 Mar; 37(1):101828. PubMed ID: 37244804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppressive and glucocorticoid therapy for the treatment of ANCA-asssociated vasculitis.
    Neumann I
    Rheumatology (Oxford); 2020 May; 59(Suppl 3):iii60-iii67. PubMed ID: 32348519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT.
    Jayne D; Walsh M; Merkel PA; Peh CA; Szpirt W; Puéchal X; Fujimoto S; Hawley C; Khalidi N; Jones R; Flossmann O; Wald R; Girard L; Levin A; Gregorini G; Harper L; Clark W; Pagnoux C; Specks U; Smyth L; Ito-Ihara T; de Zoysa J; Brezina B; Mazzetti A; McAlear CA; Reidlinger D; Mehta S; Ives N; Brettell EA; Jarrett H; Wheatley K; Broadhurst E; Casian A; Pusey CD
    Health Technol Assess; 2022 Sep; 26(38):1-60. PubMed ID: 36155131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
    Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
    Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New therapeutic strategies in lung vasculitis.
    Nasser M; Cottin V
    Curr Opin Pulm Med; 2020 Sep; 26(5):496-506. PubMed ID: 32740376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolving treatment of ANCA-associated vasculitides.
    Sauranen J; Salmela A; Kahlos K; Antonen J; Ekstrand A; Pettersson T
    Duodecim; 2016; 132(16):1449-55. PubMed ID: 29188932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
    Jones RB; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh D; Walsh M; Westman K; Jayne DR;
    N Engl J Med; 2010 Jul; 363(3):211-20. PubMed ID: 20647198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Strategies in ANCA-Associated Vasculitis.
    Emejuaiwe N
    Curr Rheumatol Rep; 2019 May; 21(7):33. PubMed ID: 31123922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab for treatment of severe renal disease in ANCA associated vasculitis.
    Geetha D; Hruskova Z; Segelmark M; Hogan J; Morgan MD; Cavero T; Eriksson P; Seo P; Manno RL; Dale J; Harper L; Tesar V; Jayne DR
    J Nephrol; 2016 Apr; 29(2):195-201. PubMed ID: 25986390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission in Nonlife-Threatening Relapses of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Randomized, Controlled Trial.
    Tuin J; Stassen PM; Bogdan DI; Broekroelofs J; van Paassen P; Cohen Tervaert JW; Sanders JS; Stegeman CA
    Clin J Am Soc Nephrol; 2019 Jul; 14(7):1021-1028. PubMed ID: 31253599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Therapies for ANCA-associated Vasculitis.
    Monti S; Brandolino F; Milanesi A; Xoxi B; Delvino P; Montecucco C
    Curr Rheumatol Rep; 2021 Apr; 23(6):38. PubMed ID: 33909172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of ANCA associated vasculitis.
    Wallace ZS; Miloslavsky EM
    BMJ; 2020 Mar; 368():m421. PubMed ID: 32188597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis.
    Pepper RJ; McAdoo SP; Moran SM; Kelly D; Scott J; Hamour S; Burns A; Griffith M; Galliford J; Levy JB; Cairns TD; Gopaluni S; Jones RB; Jayne D; Little MA; Pusey CD; Salama AD
    Rheumatology (Oxford); 2019 Feb; 58(2):260-268. PubMed ID: 30239910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Cartin-Ceba R; Indrakanti D; Specks U; Stone JH; Hoffman GS; Kallenberg CG; Langford CA; Merkel PA; Spiera RF; Monach PA; St Clair EW; Seo P; Tchao NK; Ytterberg SR; Brunetta PG; Song H; Birmingham D; Rovin BH;
    Arthritis Rheumatol; 2017 Jan; 69(1):169-175. PubMed ID: 27482943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: predefined 2-year follow-up study.
    Furuta S; Nakagomi D; Kobayashi Y; Hiraguri M; Sugiyama T; Amano K; Umibe T; Kono H; Kurasawa K; Kita Y; Matsumura R; Kaneko Y; Ninagawa K; Hiromura K; Kagami SI; Inaba Y; Hanaoka H; Ikeda K; Nakajima H;
    Ann Rheum Dis; 2024 Jan; 83(1):96-102. PubMed ID: 37734880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The management of anti-neutrophil cytoplasmic antibody-associated vasculitis: what has changed in the last 10 years?
    Suresh E
    Br J Hosp Med (Lond); 2022 Feb; 83(2):1-10. PubMed ID: 35243884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.
    Jayne DRW; Bruchfeld AN; Harper L; Schaier M; Venning MC; Hamilton P; Burst V; Grundmann F; Jadoul M; Szombati I; Tesař V; Segelmark M; Potarca A; Schall TJ; Bekker P;
    J Am Soc Nephrol; 2017 Sep; 28(9):2756-2767. PubMed ID: 28400446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Update on treatment of ANCA-associated vasculitis: Granulomatosis with polyangiitis and Microscopic Polyangiitis].
    Holle JU; Hellmich B; Moosig F
    Z Rheumatol; 2022 May; 81(4):280-285. PubMed ID: 35061059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
    Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
    Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of rituximab trials on the treatment of ANCA-associated vasculitis.
    Alberici F; Jayne DR
    Nephrol Dial Transplant; 2014 Jun; 29(6):1151-9. PubMed ID: 24126571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.